Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 21, 2017

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Opioid-Related Disorders
Interventions
DRUG

Naltrexone for extended-release injectable suspension

Opioid-dependent Drug Court clients enrolled in the study will receive monthly injections of Vivitrol for up to 12 months if they continue to be medically eligible and willing.

DRUG

Oral naltrexone

Opioid-dependent Drug Court clients enrolled in the study will receive prescriptions for oral naltrexone for up to 12 months if they continue to be medically eligible and willing.

Trial Locations (1)

27612

Fellowship Health Resources (FHR), Raleigh

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Laura and John Arnold Foundation

OTHER

collaborator

Alkermes, Inc.

INDUSTRY

collaborator

FHR (Fellowship Health Resources, Inc.)

OTHER

collaborator

Wake County Recovery Court

FED

lead

Duke University

OTHER

NCT02978417 - Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings | Biotech Hunter | Biotech Hunter